DEXCOM, INC. Cost of Revenue
DEXCOM, INC. (DXCM) reported Cost of Revenue of $478.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-07-30
- DEXCOM, INC. cost of goods and services sold for the quarter ending 2026-06-30 was $478.40M, a 2.16% increase year-over-year.
- DEXCOM, INC. cost of goods and services sold for the quarter ending 2026-03-31 was $441.60M, a 1.21% decline year-over-year.
- DEXCOM, INC. cost of goods and services sold for the quarter ending 2025-12-31 was $466.90M, a 2.01% increase year-over-year.
- DEXCOM, INC. cost of goods and services sold for the quarter ending 2025-09-30 was $477.90M, a 19.36% increase year-over-year.
- DEXCOM, INC. cost of goods and services sold for fiscal 2025 was $1.86B, a 16.64% increase from fiscal 2024.
- DEXCOM, INC. cost of goods and services sold for fiscal 2024 was $1.59B, a 19.60% increase from fiscal 2023.
- DEXCOM, INC. cost of goods and services sold for fiscal 2023 was $1.33B, a 29.87% increase from fiscal 2022.
- DEXCOM, INC. cost of goods and services sold for fiscal 2022 was $1.03B, a 33.68% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $478.40M 10-Q · filed 2026-07-30 | $920.00M 10-Q · filed 2026-07-30 | $1.39B derived: sum of 3 quarters · filed 2026-07-30 | $1.86B derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $441.60M 10-Q · filed 2026-04-30 | $908.50M derived: sum of 2 quarters · filed 2026-04-30 | $1.39B derived: sum of 3 quarters · filed 2026-04-30 | $1.85B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $466.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $944.80M derived: sum of 2 quarters · filed 2026-02-12 | $1.41B derived: sum of 3 quarters · filed 2026-07-30 | $1.86B 10-K · filed 2026-02-12 |
| 2025-09-30 | $477.90M 10-Q · filed 2025-10-30 | $946.20M derived: sum of 2 quarters · filed 2026-07-30 | $1.39B 10-Q · filed 2025-10-30 | $1.85B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $468.30M 10-Q · filed 2026-07-30 | $915.30M 10-Q · filed 2026-07-30 | $1.37B derived: sum of 3 quarters · filed 2026-07-30 | $1.77B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $447.00M 10-Q · filed 2026-04-30 | $904.70M derived: sum of 2 quarters · filed 2026-04-30 | $1.31B derived: sum of 3 quarters · filed 2026-04-30 | $1.68B derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $457.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $858.10M derived: sum of 2 quarters · filed 2026-02-12 | $1.24B derived: sum of 3 quarters · filed 2026-02-12 | $1.59B 10-K · filed 2026-02-12 |
| 2024-09-30 | $400.40M 10-Q · filed 2025-10-30 | $778.00M derived: sum of 2 quarters · filed 2025-10-30 | $1.14B 10-Q · filed 2025-10-30 | $1.51B derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | $377.60M 10-Q · filed 2025-07-30 | $736.70M 10-Q · filed 2025-07-30 | $1.11B derived: sum of 3 quarters · filed 2026-02-12 | $1.47B derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | $359.10M 10-Q · filed 2025-05-01 | $737.00M derived: sum of 2 quarters · filed 2026-02-12 | $1.09B derived: sum of 3 quarters · filed 2026-02-12 | $1.41B derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | $377.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $729.60M derived: sum of 2 quarters · filed 2026-02-12 | $1.05B derived: sum of 3 quarters · filed 2026-02-12 | $1.33B 10-K · filed 2026-02-12 |
| 2023-09-30 | $351.70M 10-Q · filed 2024-10-24 | $676.60M derived: sum of 2 quarters · filed 2024-10-24 | $955.50M 10-Q · filed 2024-10-24 | $1.23B derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | $324.90M 10-Q · filed 2024-07-25 | $603.80M 10-Q · filed 2024-07-25 | $877.70M derived: sum of 3 quarters · filed 2025-02-18 | $1.15B derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | $278.90M 10-Q · filed 2024-04-25 | $552.80M derived: sum of 2 quarters · filed 2025-02-18 | $828.20M derived: sum of 3 quarters · filed 2025-02-18 | $1.07B derived: sum of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | $273.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $549.30M derived: sum of 2 quarters · filed 2025-02-18 | $796.00M derived: sum of 3 quarters · filed 2025-02-18 | $1.03B 10-K · filed 2025-02-18 |
| 2022-09-30 | $275.40M 10-Q · filed 2023-10-26 | $522.10M derived: sum of 2 quarters · filed 2023-10-26 | $752.80M 10-Q · filed 2023-10-26 | $978.40M derived: sum of 4 quarters · filed 2024-02-08 |
| 2022-06-30 | $246.70M 10-Q · filed 2023-07-27 | $477.40M 10-Q · filed 2023-07-27 | $703.00M derived: sum of 3 quarters · filed 2024-02-08 | $906.30M derived: sum of 4 quarters · filed 2024-02-08 |
| 2022-03-31 | $230.70M 10-Q · filed 2023-04-27 | $456.30M derived: sum of 2 quarters · filed 2024-02-08 | $659.60M derived: sum of 3 quarters · filed 2024-02-08 | $837.60M derived: sum of 4 quarters · filed 2024-02-08 |
| 2021-12-31 | $225.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-08 | $428.90M derived: sum of 2 quarters · filed 2024-02-08 | $606.90M derived: sum of 3 quarters · filed 2024-02-08 | $768.00M 10-K · filed 2024-02-08 |
| 2021-09-30 | $203.30M 10-Q · filed 2022-10-27 | $381.30M derived: sum of 2 quarters · filed 2022-10-27 | $542.40M 10-Q · filed 2022-10-27 | $712.20M derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-06-30 | $178.00M 10-Q · filed 2022-07-28 | $339.10M 10-Q · filed 2022-07-28 | $508.90M derived: sum of 3 quarters · filed 2023-02-09 | $669.40M derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-03-31 | $161.10M 10-Q · filed 2022-04-28 | $330.90M derived: sum of 2 quarters · filed 2023-02-09 | $491.40M derived: sum of 3 quarters · filed 2023-02-09 | $659.10M derived: sum of 4 quarters · filed 2023-02-09 |
| 2020-12-31 | $169.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $330.30M derived: sum of 2 quarters · filed 2023-02-09 | $498.00M derived: sum of 3 quarters · filed 2023-02-09 | $646.60M 10-K · filed 2023-02-09 |
| 2020-09-30 | $160.50M 10-Q · filed 2021-10-28 | $328.20M derived: sum of 2 quarters · filed 2021-10-28 | $476.80M 10-Q · filed 2021-10-28 | $630.30M derived: sum of 4 quarters · filed 2022-02-14 |
| 2020-06-30 | $167.70M 10-Q · filed 2021-07-29 | $316.30M 10-Q · filed 2021-07-29 | $469.80M derived: sum of 3 quarters · filed 2022-02-14 | $619.20M derived: sum of 4 quarters · filed 2022-02-14 |
| 2020-03-31 | $148.60M 10-Q · filed 2021-04-29 | $302.10M derived: sum of 2 quarters · filed 2022-02-14 | $451.50M derived: sum of 3 quarters · filed 2022-02-14 | $581.40M derived: sum of 4 quarters · filed 2022-02-14 |
| 2019-12-31 | $153.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-14 | $302.90M derived: sum of 2 quarters · filed 2022-02-14 | $432.80M derived: sum of 3 quarters · filed 2022-02-14 | $544.50M 10-K · filed 2022-02-14 |
| 2019-09-30 | $149.40M 10-Q · filed 2020-10-27 | $279.30M derived: sum of 2 quarters · filed 2020-10-27 | $391.00M 10-Q · filed 2020-10-27 | $506.20M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-06-30 | $129.90M 10-Q · filed 2020-07-28 | $241.60M 10-Q · filed 2020-07-28 | $356.80M derived: sum of 3 quarters · filed 2021-02-11 | $454.90M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-03-31 | $111.70M 10-Q · filed 2020-04-28 | $226.90M derived: sum of 2 quarters · filed 2021-02-11 | $325.00M derived: sum of 3 quarters · filed 2021-02-11 | $413.90M derived: sum of 4 quarters · filed 2021-02-11 |
| 2018-12-31 | $115.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $213.30M derived: sum of 2 quarters · filed 2021-02-11 | $302.20M derived: sum of 3 quarters · filed 2021-02-11 | $367.70M 10-K · filed 2021-02-11 |
| 2018-09-30 | $98.10M 10-Q · filed 2019-11-06 | $187.00M derived: sum of 2 quarters · filed 2019-11-06 | $252.50M 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $88.90M 10-Q · filed 2019-07-31 | $154.40M 10-Q · filed 2019-07-31 | ||
| 2018-03-31 | $65.50M 10-Q · filed 2019-05-01 | |||
| 2017-12-31 | $226.40M 10-K · filed 2020-02-13 | |||
| 2016-12-31 | $194.90M 10-K · filed 2019-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| WEST PHARMACEUTICAL SERVICES INC (WST) | United States | $26.288B | 43.14 |
| BECTON DICKINSON & CO (BDX) | United States | $48.834B | 43.79 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |